These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 618241)

  • 1. [Clinical pharmacology of a new hypotensive drug with peripheral vasodilating action (ISF 2123); effects of acute intravenous administration in hypertensive patients].
    Terzoli L; Bianchini C; Cornelli U; Sala C; Leonetti G; Zanchetti A
    Boll Soc Ital Cardiol; 1977; 22(7):1053-6. PubMed ID: 618241
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of severe arterial hypertension with propyldazine (ISF 2123) associated with a diuretic and a beta-blocking agent].
    Angelino PF; Lavezzaro G; Carnovali M
    Minerva Cardioangiol; 1979 Mar; 27(3):113-8. PubMed ID: 37462
    [No Abstract]   [Full Text] [Related]  

  • 3. Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.
    van Brummelen P; Bühler FR; Kiowski W; Bolli P; Bertel O
    Int J Clin Pharmacol Biopharm; 1979 Oct; 17(10):380-5. PubMed ID: 40887
    [No Abstract]   [Full Text] [Related]  

  • 4. [Activity of a new derivative of 3-hydrazinopyridazine: ISF 2123 in patients with hypertension. I].
    Ripa R; Abbondati G; Frisoni B; Tripodi G
    Minerva Cardioangiol; 1975 Nov; 23(11):735-47. PubMed ID: 1223677
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of a new derivative of 3-hydrazine pyridazine: ISF 2123 in hypertensive patients. Note 2].
    Ripa R; Abbondati G; Frisoni B; Farabegoli E; Tripodi G
    Minerva Cardioangiol; 1975 Dec; 23(12):901-5. PubMed ID: 1232586
    [No Abstract]   [Full Text] [Related]  

  • 6. Characteristics and clinical effects of ISF 2123, a new antihypertensive agent.
    Pellegrini R; Abbondati G
    Farmaco Prat; 1977 Jan; 32(1):19-24. PubMed ID: 838036
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and haemodynamic study of a new vasodilator drug L6150 (3-[bis-(2-hydroxyethyl)amino]-6-hydrazinopyridazine) in man.
    Brod J; Bahlmann J; Cachovan M; Dahlgrün H; Prexschner P; Futterová M
    Clin Sci Mol Med Suppl; 1976 Dec; 3():601s-603s. PubMed ID: 799568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
    Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
    Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Double-blind clinical trial of a new pyridazine and its combination with reserpine in hypertensive patients].
    Di Veroli C; Petrucci D; Romeo B
    Clin Ter; 1977 Sep; 82(6):551-67. PubMed ID: 338239
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical experience with prazosin hydrochloride in arterial hypertension.
    Turner AS; Watson O; Peel JS
    N Z Med J; 1975 Mar; 81(535):240-2. PubMed ID: 1055318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension].
    Zaslavskaia RM; Komarov FI; Goncharov LF; Goncharova ZF; Makarova LA
    Klin Med (Mosk); 1998; 76(12):49-51. PubMed ID: 10067294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3-Hydrazinepyridazine derivatives. III. Synthesis and anti-hypertensive activity of new 3-(2-acylhydrazine)-pyridazine-6-alkylamino substitutes].
    Parravicini F; Scarpitta G; Dorigotti L; Pifferi G
    Farmaco Sci; 1979 Apr; 34(4):299-310. PubMed ID: 553832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Binazine--a new phthalazine derivative].
    Gamski M
    Z Gesamte Inn Med; 1973 Aug; 28(15):Suppl:234-5. PubMed ID: 4765564
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile.
    Hauger-Klevene JH; Reader C; Mayer E; Sanchez MR
    Int J Clin Pharmacol Res; 1986; 6(4):275-81. PubMed ID: 3531038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of endralazine (BQ-22-708) in patients with renal impairment and hypertension.
    Kingswood JC; Harrison PR; Banks RA; Higgs E; Mackenzie JC
    Postgrad Med J; 1983; 59 Suppl 3():173-6. PubMed ID: 6647204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound.
    Leonetti G; Terzoli L; Sala C; Bianchini C; Zanchetti A
    Clin Sci (Lond); 1980 Dec; 59 Suppl 6():461s-463s. PubMed ID: 6108817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antihypertensive treatment with nitrendipine].
    Nalin G; Beghelli G
    Minerva Cardioangiol; 1996; 44(1-2):67-72. PubMed ID: 8767626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings: Antihypertensive activity of a new 3-hydrazinopyridazine derivative: ISF 2123.
    Carpi C; Dorigotti L
    Br J Pharmacol; 1974 Nov; 52(3):459P. PubMed ID: 4458870
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of cadralazine (ISF 2469) on water-sodium balance and on essential arterial hypertension].
    Lavezzaro GC; Gastaldo D; Noussan P; Bensoni M; Parini J; Angelino PF
    Minerva Cardioangiol; 1981 Oct; 29(10):527-34. PubMed ID: 7322375
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative clinical evaluation of the effectiveness and tolerance of a new antihypertensive agent, DL 150 IT, administered alone and in combination with reserpine or propranolol].
    Glorioso S; Romeo B; Borsatti A; Todesco S
    Clin Ter; 1977 Nov; 83(3):279-99. PubMed ID: 603983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.